|[April 01, 2014]
SomaLogic Announces Dan Muehl as New Chief Financial Officer
BOULDER, Colo. --(Business Wire)--
SomaLogic, Inc., announced today that Dan Muehl has joined the company
as Chief Financial Officer (CFO). "I am delighted that Dan has agreed to
join us during this critical growth period for SomaLogic," said Byron
Hewett, Chief Executive Officer. "His financial and personal skills are
an ideal match for our culture and team, and for the challenging work
ahead of us."
"I am excited to join the SomaLogic team and to contribute to the
continued success of their hard work over the past 14 years," said Dan.
"The tremendous potential of the powerful technology they have developed
is unlike anything I have seen before, and I look forward to working
with my new colleagues to seize the many opportunities before us."
Dan joins SomaLogic with more than 28 years of financial management
experience including CFO roles at three publicly traded technology
growth companies. At SomaLogic, he will apply his expertise in finance
and operations management, strategic partnering, financing, investor
relations, compliance, and mergers and acquisitions to accelerate the
company's progress toward commercializtion of new products and services
and coordinating additional funding for continued growth. Prior to
joining SomaLogic, Dan was CFO of bio-industrial company OPX
Biotechnologies, where he closed $47 million in equity and debt
financing; vice president of finance at bio-pharmaceutical company
Pharmion (prior to its acquisition by Celgene); CFO at biotechnology
company Repligen Corporation; CFO at medical device manufacturer
Physiometrix Inc.; and CFO and chief operating officer at Number Nine
Visual Technology, a computer graphics design and manufacturing company.
Dan began his career in public accounting at Ernst & Young. He earned a
B.S. in accounting from the University of Massachusetts - Amherst and
received his CPA certificate in 1990.
Dan is taking over the CFO position from Scott Kothlow, who has chosen
to step away from the role in order to focus on other business needs at
SomaLogic. "All of us here are deeply indebted to Scott for his
steadfast and strong financial leadership this past almost 14 years,"
Said Byron Hewett. "We are also very happy that he will continue to be a
part of SomaLogic, bringing his deep experience and insight to our
SomaLogic, Inc., is a privately held biomarker discovery and clinical
diagnostics company based in Boulder, CO. The company's mission is to
use its proprietary modified aptamer-based proteomic technologies to
develop a wide range of enhanced protein-analysis tools and reagents for
the life sciences community, to facilitate biomarker discovery and
validation for diagnostic and therapeutic applications, and to develop
and commercialize clinical diagnostic products that will improve the
delivery of health care by offering timely and accurate diagnostic
information to physicians and their patients. Further information about
SomaLogic can be found at www.somalogic.com.
[ InfoTech Spotlight's Homepage ]